作者
Robert M Grant, Javier R Lama, Peter L Anderson, Vanessa McMahan, Albert Y Liu, Lorena Vargas, Pedro Goicochea, Martín Casapía, Juan Vicente Guanira-Carranza, Maria E Ramirez-Cardich, Orlando Montoya-Herrera, Telmo Fernández, Valdilea G Veloso, Susan P Buchbinder, Suwat Chariyalertsak, Mauro Schechter, Linda-Gail Bekker, Kenneth H Mayer, Esper Georges Kallás, K Rivet Amico, Kathleen Mulligan, Lane R Bushman, Robert J Hance, Carmela Ganoza, Patricia Defechereux, Brian Postle, Furong Wang, J Jeff McConnell, Jia-Hua Zheng, Jeanny Lee, James F Rooney, Howard S Jaffe, Ana I Martinez, David N Burns, David V Glidden
发表日期
2010/12/30
期刊
New England Journal of Medicine
卷号
363
期号
27
页码范围
2587-2599
出版商
Massachusetts Medical Society
简介
Background
Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition.
Methods
We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC–TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections.
Results
The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC–TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; P=0.005). In the FTC …
引用总数
学术搜索中的文章
RM Grant, JR Lama, PL Anderson, V McMahan, AY Liu… - New England Journal of Medicine, 2010